ライフサイエンスコーパス: latency-associated peptide

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 e not mediated by direct modification of its latency-associated peptide.

2 anti-MMP-9 antibodies as well as by TGF-beta latency-associated peptide.

3 a role in its interaction with the TGF-beta1 latency-associated peptide.

4 ations to promote alpha(v)beta(6) binding to latency-associated peptide and to the ligand-mimetic ant

5 latent complex (LLC) comprised of TGF-beta1, latency-associated peptide, and latent TGF-beta binding

6 mino acid pro region of TGF-beta1, the beta1-latency-associated peptide (beta1-LAP), is noncovalently

7 of Foxp3 or transforming growth factor beta-latency-associated peptide expressed by THi cells.

8 Ultimately, latency-associated peptide expressing CD4(+) regulatory

9 pro-TGF-beta protein as measured by surface latency-associated peptide expression but yet were unabl

10 a-dependent biomarker CD103, suggesting that latency-associated peptide expression is not always cong

11 alpha v beta6 (foot-and-mouth-disease virus, latency associated peptide), have a common structure com

12 The protein complex of TGF-beta and its latency-associated peptide is conjugated onto SWCNTs, wh

13 tent TGF-beta complex, which consists of the latency associated peptide (LAP) secreted in non-covalen

14 g growth factor beta (TGF-beta), decorin and latency associated peptide (LAP), to reverse depressed T

15 h plays roles in targeting and activation, a latency associated peptide (LAP), which regulates latenc

16 We have identified latency-associated peptide (LAP) and IL-1 receptor type

17 gulatory cells have been reported to express latency-associated peptide (LAP) and TGF-beta on the sur

18 beta) is secreted as a latent complex of the latency-associated peptide (LAP) and the mature domain,

19 s of TGF-beta1 noncovalently associated with latency-associated peptide (LAP) and which can be activa

20 We found that TGF-beta complexed to latency-associated peptide (LAP) is expressed on the cel

21 We now report that the latency-associated peptide (LAP) of the latent TGF-beta

22 uction of a regulatory T-cell that expresses latency-associated peptide (LAP) on its surface.

23 l subset of CD4(+)CD25(+) Tregs that express latency-associated peptide (LAP) on their cell surface (

24 s and lung-draining lymph nodes that express latency-associated peptide (LAP) on their cell surface b

25 + CD25- LAP+ regulatory T cells that contain latency-associated peptide (LAP) on their surface and th

26 were generated in the presence of TGF-beta1 latency-associated peptide (LAP) or TGF-beta1 neutralizi

27 GF) beta 1 (LC 1-30) but not with TGF-beta 1 latency-associated peptide (LAP) protein (266-278); at 1

28 Nasal anti-CD3 induced a CD4(+)CD25(-)latency-associated peptide (LAP)(+) regulatory T cell th

29 gulatory gammadelta T cells that express the latency-associated peptide (LAP), a membrane-bound TGF-b

30 rs are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from

31 ssing a membrane bound form of TGF-beta, the latency-associated peptide (LAP), and having regulatory

32 ntained markedly higher expression levels of latency-associated peptide (LAP), CD103, PD-1, PD-L1, an

33 It has been reported that pro-TGF-beta, latency-associated peptide (LAP), latent TGF-beta and/or

34 as an inactive (latent) form in complex with latency-associated peptide (LAP), which is disulfide bon

35 We induced TGF-beta-dependent CD4(+) latency-associated peptide (LAP)-positive Tregs by oral

36 lly found in the latent form associated with latency-associated peptide (LAP).

37 rface of ex vivo immature human DCs bound by latency-associated peptide (LAP).

38 lly occurring antagonist to TGF-beta1, human latency-associated peptide (LAP).

39 in which it is noncovalently associated with latency-associated peptide (LAP).

40 h its processed propeptide dimer, called the latency-associated peptide (LAP); the complex of the two

41 that express latent membrane-bound TGF-beta (latency-associated peptide [LAP]) and have been shown to

42 which it is bound to its cleaved prodomain (latency-associated peptide [LAP]) and, via LAP, to laten

43 atent complex with its processed propeptide (latency-associated peptide [LAP]).

44 alently associated proregions, also known as latency-associated peptides (LAPs).

45 nhibits binding to all ligands including the latency-associated peptide of TGF-beta.

46 her TGF-beta1-blocking molecule, recombinant latency-associated peptide of TGF-beta1 (rLAP), also rev

47 evented direct binding of fibroblasts to the latency-associated peptide of TGF-beta1 and prevented ac

48 bound to the small latent complex and to the latency-associated peptide of TGF-beta1 and that this bi

49 Latency-associated peptide of transforming growth factor

50 bioactive TGF-beta entity and its N-terminal latency-associated peptide prodomain.

51 sues as a biologically inactive complex with latency-associated peptide, requires extracellular modif

52 Latent TGF-beta binding protein 1, latency-associated peptide, TGF-beta1, clusterin, von Wi

53 tionally active receptor for fibronectin and latency-associated peptide-TGF-beta1; it mediates attach

54 tly on IL-10(+) (26.3 +/- 5.8%) and on a few latency-associated peptide/TGF-beta1(+) (18.1 +/- 1.9%)

55 e enriched in CD25(high), CD25(+)CD127(low), latency-associated peptide/TGF-beta1, and CCR4-expressin

56 igrate on an alphavbeta6 specific substrate, latency-associated peptide-TGFbeta, to a greater extent

57 ic interleukin 10 (IL-10) and membrane-bound latency-associated peptide/transforming growth factor be

58 ed with either antibodies to TGF-beta or the latency associated peptide, which neutralize TGF-beta.

59 ased IGFBP-3 mRNA levels, but treatment with latency-associated peptide, which inactivates secreted T

60 eted as a biologically inactive complex with latency-associated peptide, which must be modified by lo

61 a(6) to the transforming growth factor-beta1 latency-associated peptide with IC(50) values as low as

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。